Organon & Co. Common Stock (NY:OGN)

Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5.3% year on year to $1.51 billion. The company’s full-year revenue guidance of $6.2...

Topics Economy

OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook

February 13, 2026

Organon (OGN) Q4 2025 Earnings Call Transcript

Organon (OGN) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

Via The Motley Fool

Topics Earnings

Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook ↗

February 12, 2026

Via Chartmill

Topics Earnings

Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations

February 12, 2026

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025

February 12, 2026

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know.

Organon Earnings: What To Look For From OGN

February 10, 2026

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but...

Topics Artificial Intelligence World Trade

2 Healthcare Stocks with Promising Prospects and 1 We Brush Off

February 04, 2026

Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Topics Stocks

January 29, 2026

Organon Completes Divestiture of JADA® System to Laborie

January 28, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Nasdaq, S&P 500 Futures Rise As Trump Diffuses Tariff Risk: Why INTC, MSFT, NFLX, RKLB, OGN Are On Traders' Radar Today ↗

January 22, 2026

Retail sentiment on Stocktwits for SPY and QQQ remains ‘bearish,’ signaling caution.

Via Stocktwits

Topics ETFs Earnings Economy

Why Are Organon (OGN) Shares Soaring Today

January 20, 2026

Shares of pharmaceutical company Organon (NYSE:OGN) jumped 8.9% in the afternoon session after reports surfaced that Sun Pharmaceutical Industries submitted a non-binding proposal to acquire the...

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque

Topics Artificial Intelligence Initial Public Offering Supply Chain

January 16, 2026

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

3 Small-Cap Stocks We Approach with Caution

January 07, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have...

3 Healthcare Stocks with Questionable Fundamentals

December 15, 2025

Shares of pharmaceutical company Organon (NYSE:OGN) fell 4.7% in the afternoon session after Barclays initiated coverage on the company with an 'Underweight' rating and a price target of $7.50. The new...

Topics Stocks

Why Organon (OGN) Shares Are Trading Lower Today

December 09, 2025

Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be...

Topics Initial Public Offering

3 Stocks Under $10 We Steer Clear Of

December 08, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

3 Value Stocks with Questionable Fundamentals

December 04, 2025

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

3 Cash-Producing Stocks We Find Risky

December 03, 2025

Over the past six months, Organon’s stock price fell to $7.77. Shareholders have lost 16.1% of their capital, which is disappointing considering the S&P 500 has climbed by 14.7%. This may have...

Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings?

November 30, 2025

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Organon (NYSE:OGN) and its peers.

Topics Stocks

Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks

November 25, 2025

Topics Artificial Intelligence Intellectual Property

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

November 17, 2025

Organon's third quarter was marked by better-than-expected top-line and bottom-line results, which were well received by the market. Management attributed the quarter’s outperformance to strong...

The 5 Most Interesting Analyst Questions From Organon’s Q3 Earnings Call

November 17, 2025

Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN

Topics Earnings

November 14, 2025

From Kahn Swick & Foti, LLC

Shares of pharmaceutical company Organon (NYSE:OGN) fell 2.9% in the afternoon session after the company lowered its full-year sales guidance and analysts subsequently cut their price targets on the...

Organon (OGN) Stock Trades Down, Here Is Why

November 11, 2025

Pharmaceutical company Organon (NYSE:OGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 1.3% year on year to $1.60 billion. On the other hand, the company’s...

Topics Artificial Intelligence Initial Public Offering Supply Chain

Organon Analysts Cut Their Forecasts Following Q3 Results ↗

November 11, 2025

Via Benzinga

OGN Q3 2025 Deep Dive: Leadership Changes, Portfolio Shifts, and Guidance Recalibration

November 11, 2025